News

The US Food and Drug Administration (FDA) has approved Contrave as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with

In 2011, MedImmune licensed the OX40 agonist platform from AgonOx as a result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the

The company said that the drug candidate in the ALS trial is called as GM604 and GM608 in the PD trial. For the treatment of ALS, the company

In a poster at the American Society of Human Genetics (ASHG) Annual Meeting, Daniel G. Bichet, M.D., M.Sc., Professor, Department of Physiology, University of Montreal, presented results from

The median number of injections using the protocol-specified retreatment regimen was one fewer in patients treated with EYLEA compared to bevacizumab and ranibizumab. Fewer patients in the EYLEA

Development of the vaccine candidate is progressing at an unprecedented rate, with first phase 1 safety trials with the vaccine candidate underway in the USA, UK and Mali,

These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 ("PCSK9"). By its complaint, Amgen seeks an injunction to prevent

The CFDA inspected Shandong Taibang’s new coagulation factor production facility for Good Manufacturing Practices ("GMP") compliance in June 2013 and is expected to issue the GMP certificate before

Pennsaid 2% is a topical product containing 2% diclofenac sodium compared to 1.5% for original Pennsaid and it is approved in the US to treat pain of osteoarthritis